Zai Lab (NASDAQ:ZLAB) CFO Sells $106,007.61 in Stock

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CFO Yajing Chen sold 5,199 shares of the stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $20.39, for a total value of $106,007.61. Following the completion of the sale, the chief financial officer owned 32,558 shares in the company, valued at approximately $663,857.62. The trade was a 13.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Yajing Chen also recently made the following trade(s):

• On Friday, March 13th, Yajing Chen sold 1,703 shares of Zai Lab stock. The shares were sold at an average price of $18.63, for a total value of $31,726.89.

Zai Lab Stock Performance

Zai Lab stock remained flat at $20.41 during mid-day trading on Friday. The company’s stock had a trading volume of 707,427 shares, compared to its average volume of 746,471. The company has a 50 day simple moving average of $18.63 and a 200 day simple moving average of $21.91. Zai Lab Limited Unsponsored ADR has a 12 month low of $15.96 and a 12 month high of $44.34. The company has a market capitalization of $2.30 billion, a PE ratio of -12.68 and a beta of 0.86.

Zai Lab (NASDAQ:ZLAB) last released its earnings results on Saturday, February 14th. The company reported ($0.50) earnings per share for the quarter. The business had revenue of $127.60 million for the quarter. Zai Lab had a negative return on equity of 22.81% and a negative net margin of 38.15%. Analysts expect that Zai Lab Limited Unsponsored ADR will post -2.58 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Zai Lab

An institutional investor recently raised its position in Zai Lab stock. SG Americas Securities LLC lifted its holdings in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 6.6% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 10,396 shares of the company’s stock after purchasing an additional 642 shares during the period. SG Americas Securities LLC’s holdings in Zai Lab were worth $183,000 at the end of the most recent quarter. Institutional investors and hedge funds own 41.65% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Jefferies Financial Group upgraded shares of Zai Lab to a “strong-buy” rating in a research note on Monday, January 19th. Zacks Research lowered Zai Lab from a “hold” rating to a “strong sell” rating in a report on Friday, January 23rd. JPMorgan Chase & Co. reduced their price objective on Zai Lab from $39.00 to $32.00 and set an “overweight” rating on the stock in a report on Wednesday, March 18th. UBS Group assumed coverage on Zai Lab in a research report on Wednesday, January 7th. They set a “buy” rating and a $35.00 target price for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Zai Lab in a report on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $50.00.

About Zai Lab

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.